A Surprise Premiere Catches Telluride Off Guard
Filmmakers Nathan Fielder and Lance Oppenheim arrived at the Telluride Film Festival on Sunday with a documentary no one had seen coming. Their film, “You Can See Everything,” was kept under wraps until it screened, and the audience’s reaction reflected exactly what the secrecy suggested – something out of the ordinary had been put on screen.
What set the film apart, according to those in attendance, was the degree of access Fielder and Oppenheim secured with Elizabeth Holmes, the Theranos founder convicted of fraud. Access to Holmes at this point in her story – post-trial, post-sentencing – is not something filmmakers have managed before at this level.
Why This Film Is Different From What Came Before
The Theranos story has already been picked over extensively. There have been books, a Hulu series, podcasts, and prior documentaries – each attempting to explain how a charismatic Stanford dropout convinced the medical and venture capital worlds that her company had revolutionized blood testing, when in fact the technology never worked as advertised. Holmes was convicted in January 2022 on four counts of fraud and began serving an 11-year federal prison sentence in May 2023.
What Fielder and Oppenheim appear to have done differently is go directly to the source in a way that produced something audiences at Telluride described as stunning. The word “generous” in characterizing the access carries weight here – this is not archival footage, narrated timelines, or second-hand recollection. The film brings Holmes into the frame in a manner that prior projects either could not or chose not to pursue.
Fielder is best known for his Comedy Central series Nathan For You and HBO’s The Rehearsal, both of which operate in an uneasy space between documentary and constructed reality. His methods tend to involve sustained, intimate engagement with subjects in ways that can be disarming – sometimes to comedic effect, sometimes to something closer to genuine exposure. Applying that approach to Holmes, one of the most heavily documented fraudsters in Silicon Valley history, is a meaningful creative choice.
Telluride as a Launch Point
Telluride has a long history of surprise premieres. The festival, held annually in Colorado over Labor Day weekend, has been used to debut films that go on to define awards seasons – and occasionally, to launch projects that generate cultural conversation well beyond cinema circles. Dropping “You Can See Everything” there without prior announcement fits a pattern of using Telluride’s concentrated, film-literate audience as a pressure test before wider distribution.
Sunday night’s screening landed with enough force that it became the talking point coming out of the festival’s opening days. For a story that many assumed had been fully told, that reaction suggests Fielder and Oppenheim found an angle – or an admission, or a moment – that the prior wave of Theranos content did not reach.
What the Access Actually Means
Holmes’s willingness to participate is itself a significant data point. Since her conviction, she has not been a public presence in any meaningful sense. Her legal team spent years pursuing appeals and attempting to delay reporting to prison. Granting a documentary crew extended access – access described as generous by those who watched the result – indicates either a strategic calculation about her public legacy, or a level of trust she placed in Fielder and Oppenheim specifically.
Fielder’s track record makes the latter plausible. His subjects on The Rehearsal often opened up in ways that seemed to surprise even themselves, partly because his approach creates unusual conditions for candor. Whether that same dynamic applies here, and what Holmes actually says or reveals in the film, will become clearer as “You Can See Everything” moves toward broader release.
The timing also matters. Holmes entered federal prison in May 2023. The production and editing of a feature documentary takes time – which means filming likely took place either before she reported to prison, during supervised periods, or through some combination of access points. The film’s structure around that timeline would tell audiences something about what kind of portrait Fielder and Oppenheim were building and when they decided the story was complete enough to screen.
Theranos raised roughly $945 million from investors over its lifetime. Holmes, at her peak, was valued by Forbes at $4.5 billion before the magazine retracted that figure entirely. The investors, patients who received unreliable blood test results, and employees who believed in the company’s mission have all been subjects of prior coverage. Whether this documentary shifts focus toward Holmes herself – her interiority, her account, her present state – or continues interrogating the systemic failures that let Theranos operate as long as it did, is the question the Telluride premiere raises without yet fully answering.
The film has no confirmed wide release date as of the Telluride premiere. Festivals don’t distribute – they reveal.
